ACCESS Newswire

Biovica International

Share
Promising DiviTumTKa Results from BioItaLEE Study Presented at ESMO

UPPSALA, SE / ACCESSWIRE / September 14, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)

Biovica, active in cancer diagnostics, today announces that DiviTumTKa results from the large BioItaLEE study will be presented as a poster during the European Society for Medical Oncology (ESMO) meeting 16 to 21 September 2021. The results strengthen the potential of DiviTum ® TKa as a treatment monitoring devise for CDK4/6 inhibitor treatments.

The results from a large independent study with a CDK4/6 inhibitor therapy and DiviTum ® TKa as a treatment monitoring assay in 287 patients with metastatic breast cancer is presented at the ESMO congress.

"I'm happy to see that the presented results on this CDK4/6 inhibitor ribociclib are consistent with earlier CDK4/6-results for example for palbociclib. The study results are highly encouraging as a reference for using DiviTum®TKa for the monitoring of CDK4/6 inhibitor treatments in HR positive metastatic breast cancer," said Anders Rylander, CEO of Biovica.

The study concludes that TKa appears to be a new promising prognostic, predictive and monitoring biomarker in patients with HR positive/HER2 negative metastatic breast cancer treated with ribociclib plus letrozole as first-line therapy. Baseline and dynamic TKa changes provided independent valuable information. Lack of TKa suppression at day 15 indicates enrichment for primary resistance and poor prognosis. TKa rebound at treatment cycle 2, day 1 may indicate early adaptation to ribociclib plus letrozole, while persistent suppression seems to identify patients with sustained inhibition and excellent prognosis.

Link to poster: https://cslide.ctimeetingtech.com/esmo2021/attendee/confcal_4/presentation/list?q=292P+-+

Contact

Anders Rylander, CEO
Phone: +46-18-444 48 35
E-mail: anders.rylander@biovica.com

Biovica - Treatment decisions with greater confidence

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum ® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se , +46 8 528 00 399. For more information please visit: www.biovica.com .

Attachments

Promising DiviTumTKa results from BioItaLEE study presented at ESMO

SOURCE: Biovica International



View source version on accesswire.com:
https://www.accesswire.com/663954/Promising-DiviTumTKa-Results-from-BioItaLEE-Study-Presented-at-ESMO

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Camino Announces High-Grade Copper, with Bornite, Trench Results of 90 Meters at 1.07 % Copper including 4 Meters at 3.05% Copper in New Mirador Zone at Los Chapitos in Peru16.7.2025 12:00:00 CEST | Press release

Appoints New CFO for the Copper Development Stage in Chile and Peru VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ("Camino" or the "Company") is pleased to announce high‐grade copper trench results from the Mirador prospect located in the Diva trend, one of several prospective targets at the Company's Los Chapitos Copper Project ("Los Chapitos" or the "Project") in Peru. The new mineralized body identified at Mirador could represent the northwesterly continuation of the Adriana mineralized copper zone where over 20,000 meters of drilling has been completed. There are clear lithological, mineralogical, and structural similarities observed at Adriana, Mirador, and Katty that share the same structural control across the Diva trend fault. Importantly, this primary and oxide copper surface exposure mineralization is within intrusive, potential source rocks, that typically underlay the volcanic Chocolate Formation. The package of vol

Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release

Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust

FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release

WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr

U.S. Polo Assn. Celebrates Seventh Year Supporting the 2025 Outsourcing Inc. Royal Charity Polo Cup15.7.2025 13:00:00 CEST | Press release

Official Apparel and Team Sponsor Delivers a Commemorative Gift Collection Honoring the Global Sport Brand's 135th Anniversary Celebration WEST PALM BEACH, FLA. AND WINDSOR, U.K. / ACCESS Newswire / July 15, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), in partnership with Brand Machine Group (BMG), its licensing partner in the United Kingdom, proudly served once again as the Official Apparel and Team Sponsor for the 2025 Outsourcing Inc. Royal Charity Polo Cup. The prestigious event took place on July 11 at the renowned Windsor Great Park at Flemish Farms' Guards Polo Club.U.S. Polo Assn. (left to right) U.S. Polo Assn. Team Accepts Royal Charity Polo Cup Trophy: James Beim, HRH The Prince of Wales, J. Michael Prince (USPA Global), Boo Jalil (BMG), Aiyawatt Srivaddhanaprahba, and Amr Zeden In its seventh consecutive year of sponsorship for the charitable event, U.S. Polo Assn. outfitted all participating polo players, umpires, and flaggers in

QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release

BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye